FiercePharma5h
With Blenrep's revival, GSK dials up long-term sales goal—again—despite RSV vaccine woes
Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...
BioPharma Dive2h
GSK, Pfizer sales of RSV shots slow as vaccination rates ebb
Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their use.
Neurology Advisor5h
COVID-19 Linked to More Severe Outcomes Than Flu, RSV in 2022-2023 Season
COVID-19 was associated with more severe disease outcomes than influenza or respiratory syncytial virus (RSV) during the 2022 to 2023 season.
Shionogi's RSV antiviral shows promise in hVIVO trial
LONDON - Shionogi & Co., Ltd. (TYO:4507) has reported positive outcomes from its Phase 2a human challenge trial for an investigational oral antiviral candidate targeting Respiratory Syncytial Virus ...